Skip to main content
  • Home
  • A Review of Emerging ARNI Data in HFrEF

A Review of Emerging ARNI Data in HFrEF

Topic:
  • Heart Failure

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Overview

Despite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.

 

Despite this evidence and the recommendation of clinical guidelines, ARNI therapy is not initiated in the majority of eligible patients. Evidence suggests a lack of understanding of a patient’s risk and also the benefit of life saving therapies by physicians is a primary cause of under-utilization.

 

Increased education is needed so clinicians fully understand the patient’s risk, as well as latest mechanistic and clinical data to ensure confidence in using newer therapies.

 

This educational program summarises new data covering ARNI therapy for heart failure with reduced ejection fraction (HFrEF) presented at the European Society of Cardiology (ESC) 2019 congress.

Disclosure

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

 

This activity has been supported by an unrestricted educational grant from Novartis.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

Target Audience

This programme is intended to educate:

  • Heart Failure Specialists
  • General Cardiologists

Learning Objectives

  • Review updated data of ARNI therapy for HFrEF present at the ESC 2019;
  • understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases);
  • interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data;
  • apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized; patients
  • Apply clinical and real-world evidence data for the treatment HFrEF with ARNI therapy.
Register now Log in
2.

ARIADNE in Review

Duration:

Speakers: Uwe Zeymer (Klinikum Ludwigshafen, DE)

4.

PROVE-HF in Review

Duration:

Speakers: James Januzzi (Harvard Medical School, MA, US)

5.

EVALUATE-HF in Review

Duration:

Speakers: Akshay Desai (Harvard Medical School, MA, US)

6.

Commentary on the PROVE-HF and the EVALUATE-HF Trials

Duration:

Speakers: Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)

7.

TRANSITION-CHF in Review

Duration:

Speakers: Rolf Wachter (Universität Leipzig, Leipzig, DE)

8.

PIONEER in Review

Duration:

Speakers: David Morrow (Harvard Medical School, MA, US)

9.

Commentary on the TRANSITION-CHF and the PIONEER Trials

Duration:

Speakers: Andrew Coats (University of Warwick) Scott Solomon (Harvard Medical School, MA, US)

Course Director

Andrew Coats

Monash University, AU and University of Warwick, UK

Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.

View full profile

Scott Solomon

Brigham and Women's Hospital, Boston, US / Harvard Medical School

Prof Scott D Solomon is the Edward D Frohlich Distinguished Chair at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital.

View full profile

Speaker

Uwe Zeymer

Klinikum Ludwigshafen, Ludwigshafen, DE

Professor Uwe Zeymer is an interventional cardiologist at the Klinikum Ludwigshafen (Germany). His interests include acute cardiac care and acute coronary syndromes.

View full profile

James Januzzi

Massachusetts General Hospital

Dr James L Januzzi,  is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has an in-depht experience as a teacher and leads a research programme with specific focus on cardiac biomarker testing.

View full profile

Akshay Desai

Brigham and Women’s Hospital, Boston, MA, US

Prof Akshay Desai is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital. Dr Desai’s research focuses on improving care and outcomes for HF patients, as well as strategies to reduce heart failure readmissions. 

View full profile

Rolf Wachter

University of Leipzig, Leipzig, Germany

Prof Rolf Wachter is Director of Cardiology at the Clinic and Policlinic for Cardiology, University Hospital Leipzig. Prior to this, he served as Deputy Director (Leitender Oberarzt), Clinic for Cardiology and Pneumology, University Medicine Göttingen, Germany.

View full profile

David Morrow

Cardiovascular Division, Brisham and Women’s Hospital

Prof David A Morrow the Director of the Samuel A. Levine Cardiac Intensive Care Unit in the Division of Cardiovascular Medicine at Brigham and Women's Hospital and a Professor of Medicine at Harvard Medical School. He directs the TIMI Biomarker Program

View full profile

The event ‘A Review of Emerging ARNI Data in HFrEF’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

 

AVAILABLE CREDIT

1.00 European Board for Accreditation in Cardiology (EBAC)

Related Courses

SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more
Making Gains in HFpEF: An Appraisal of Where We Are Now

Learning objectives

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
See more
Heart Failure Management in a Changing Paradigm
  • 1 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
  • InIncorporate quality of life measures for assessing therapeutic efficacy in HF
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
See more
The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?

Learning objectives

  • Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
  • Compare updates from the ACC with the 2021 ESC HF guidelines
  • Recall guideline recommendations for the initiation of foundational therapy for heart failure
  • Adopt foundational GMDT early in the disease course
  • Postulate how ejection fraction will be used in future trials and in future guidelines
  • Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
See more
HFO 2022 - Session 3.3: Live Case & Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 3.1 & 3.2: Quality of Life and Multi-disciplinary Care in HF
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.5 Practical Theory & Hot Topics: Advanced HF Care
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.3 Practical Theory & Hot Topics: HF Aetiology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.2 Live Case and Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 1.4 Practical Theory & Hot Topics: Transitioning Care and Monitoring Technology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more